News Industry News Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure December 10, 2015
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015
News Industry News Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure May 22, 2015